Figure 7.

Eri is active for cells from healthy humans, IAV patients or gout patients. (A, B) Freshly isolated PBMCs from donor #1 (A) and donor #2 (B) were treated with or without LPS (1 μg/ml) for 3 h. Then, cells were treated with or without nigericin (2 μM) or Eri (5 nM) for 3 h. IL-1β (left panel) and TNF-α (middle panel) protein levels were determined by ELISA, or mature IL-1β and p20 in supernatants or pro-IL-1β and pro-Casp-1 in lysates were determined by western blot (right panel). (C, D) Freshly isolated PBMCs from health donor, IAV patient #1 (C) or IAV patient #2 (D) were treated with Eri (5 nM) for 6 h. IL-1β (left panel) and TNF- (middle panel) protein levels were determined by ELISA, or mature IL-1β and p20 in supernatants or pro-IL-1β and pro-Casp-1 in lysates were determined by western blot (right panel). (E, F) Experiments were performed as described in (C, D), except SFCs from gout patients were used. All experiments were repeated at least three times. Bar graphs present means ± SEM, (**P < 0.01). n.s., not significant.